



Medicare Part B Preferred drug list — Aetna Better Health® Premier Plan MMAI (Medicare-Medicaid Plan)

Some medically administered Part B drugs may have extra requirements or limits on coverage. These may include step therapy. This is when we require you to first try certain preferred drugs to treat your medical condition before covering another non-preferred drug.

For example, if drug A and drug B both treat your condition, we may prefer drug A, and require you to try it first. If drug A does not work for you, we will then cover drug B. The listed preferred products should be used first. An exception process is in place for specific cases that may call for a non-preferred product.

Drug classes with preferred products are listed below. For specific medical indications subject to step therapy, please see the corresponding clinical policy bulletin on the Aetna® website.

To find out more, go to [AetnaBetterHealth.com/Illinois](https://www.aetna.com/illinois). You can also call us at the number on your ID card.

Drug Class/Indication(s)	Non-Preferred Product(s)	Preferred Product(s)
<i>Alpha-1 proteinase inhibitors</i>	Aralast NP Glassia Zemaira (through 8/31/24)	Prolastin-C Zemaira (effective 9/1/24)
<i>Bone Resorption Inhibitors</i> • Hypercalcemia of malignancy	Xgeva	Pamidronate Zoledronic acid
<i>Botulinum Toxins</i> • Blepharospasm • Cervical dystonia • Chronic sialorrhea • Upper limb spasticity	Daxxify Dysport Myobloc	Botox Xeomin
<i>Botulinum Toxins</i> • All other indications		Botox
<i>Complement Inhibitors</i> • Hemolytic uremic syndrome • Myasthenia gravis • Paroxysmal nocturnal hemoglobinuria		Soliris Ultomiris
<i>Complement Inhibitors</i> • <i>Neuromyelitis optica spectrum disorder</i>		Soliris

<i>CSF — Leukocyte Growth Factors (filgrastim)</i>	Granix Leukine Neupogen Nivestym Releuko	Zarxio
<i>CSF — Leukocyte Growth Factors (pegfilgrastim)</i>	Fylnetra Nyvepria Rolvedon Ryzneuta (effective 9/1/24) Stimufend Udenyca Udenyca Onbody	Fulphila Neulasta Neulasta Onpro
<i>Erythropoiesis Stimulating Agents</i> <ul style="list-style-type: none"> Anemia due to chronic kidney disease Anemia due to chemotherapy 	Epogen Retacrit Jesduvroq	Aranesp Procrit
<i>Erythropoiesis Stimulating Agents</i> <ul style="list-style-type: none"> Anemia due to Zidovudine use in HIV Transfusion reduction for select surgeries 		Procrit
<i>Enzyme replacement therapy</i>	Vpriv	Cerezyme Elelyso
<i>Factor VIII (recombinant)</i> <ul style="list-style-type: none"> Hemophilia A (prophylaxis) 	Advate Afstyla Nuwiq NovoEight Xyntha	Kovaltry
<i>Gonadotropin-Releasing Hormone Agonists</i> <ul style="list-style-type: none"> Advanced prostate cancer 	Lupron depot Trelstar Zoladex	Eligard
<i>Gonadotropin-Releasing Hormone Antagonists</i>		Firmagon
<i>Immunologics (B through B)</i> <ul style="list-style-type: none"> Ulcerative colitis 	Avsola Omvoh (effective 9/1/24) Renflexis	Inflectra Entyvio Remicade Unbranded infliximab
<i>Immunologics (B through B)</i> <ul style="list-style-type: none"> Crohn's disease 		Entyvio
<i>Intravenous iron</i>	Feraheme Injectafer Monoferric	Ferrlecit Sodium ferric gluconate Infed

<ul style="list-style-type: none"> Iron deficiency anemia after intolerance or unsatisfactory response to oral iron 		Venofer
<i>IVIg (intravenous immunoglobulin)</i>	Asceniv Bivigam Flebogamma Gammagard Liquid Gammagard S/D Gammaplex Panzyga	Gammaked Gamunex-C Octagam Privigen
<i>SCIG (subcutaneous immunoglobulin)</i>	Cutaquig Cuvitru Gammagard Liquid HyQvia	Gammaked Gamunex-C Hizentra Xembify
<i>Multiple sclerosis</i>		Tysabri
<i>Oncology</i> <ul style="list-style-type: none"> Breast cancer 	Perjeta	Phesgo
<i>Oncology (Abraxane)</i>	Abraxane Paclitaxel (protein bound)	Docetaxel Paclitaxel
<i>Oncology (Avastin)</i>	Alymsys Avastin Avzivi (effective 9/1/24) Vegzelma	Mvasi Zirabev
<i>Oncology (Herceptin)</i>	Herceptin Herceptin Hylecta Herzuma Ogivri Ontruzant	Kanjinti Trazimera
<i>Oncology (Multiple myeloma)</i>	Darzalex Darzalex Faspro Empliciti Kyprolis Sarclisa	Bortezomib
<i>Oncology (PD1/PDL1)</i> <ul style="list-style-type: none"> Squamous cell carcinoma 	Keytruda	Libtayo

<p><i>Oncology (PD1/PDL1)</i></p> <ul style="list-style-type: none"> • Non-small cell lung cancer 	Imfinzi Keytruda Opdivo Tecentriq	Libtayo
<p><i>Oncology (Pemetrexed)</i></p>	Pemfexy	Alimta Pemetrexed
<p><i>Oncology (Rituximab)</i></p> <ul style="list-style-type: none"> • All requests except rheumatoid arthritis 	Riabni Rituxan Rituxan Hycela	Ruxience Truxima
<p><i>Osteoarthritis</i></p>	Zilretta	Kenalog Depo-medrol Triamcinolone acetonide Methylprednisolone acetate
<p><i>Severe asthma</i></p>	Cinqair Nucala Xolair	Fasenra
<p><i>Somatostatin analogues</i></p>	Lanreotide (Cipla) Signifor LAR	Sandostatin LAR Somatuline depot
<p><i>VEGF inhibitors (ophthalmic)</i></p>	Beovu Cimerli Lucentis Susvimo Vabysmo	Bevacizumab (Avastin) Byooviz or Eylea/Eylea HD after trial/failure of bevacizumab (Avastin)
<p><i>Viscosupplements (single injection)</i></p>	Gel-One Monovisc	Durolane Synvisc-One
<p><i>Viscosupplements (multiple injections)</i></p>	Gelsyn-3 GenVisc Hyalgan Hymovis Orthovisc Supartz FX TriVisc Visco-3	Euflexxa Synvisc

For the following classes, preferred products may be covered under the Part D (pharmacy) benefit:

Drug Class	Non-preferred Product(s)	Preferred Product(s)*
<i>Bone Resorption Inhibitors</i> <ul style="list-style-type: none"> Osteoporosis 	Evenity	Teriparatide
<i>Immunologics</i> <ul style="list-style-type: none"> Crohn's disease 	Actemra Avsola Cimzia Ilumya	Humira Rinvoq Skyrizi Stelara
<i>Immunologics</i> <ul style="list-style-type: none"> Ankylosing spondylitis 	Inflectra Orencia Remicade Renflexis	Enbrel Humira Xeljanz/Xeljanz XR Rinvoq
<i>Immunologics</i> <ul style="list-style-type: none"> Juvenile idiopathic arthritis 	Riabni Rituxan Ruxience	Enbrel Humira Xeljanz
<i>Immunologics</i> <ul style="list-style-type: none"> Plaque psoriasis 	Simponi Aria Truxima Tyruko Tysabri Unbranded infliximab	Enbrel Humira Otezla Skyrizi Stelara Tremfya (effective 9/1/24)
<i>Immunologics</i> <ul style="list-style-type: none"> Psoriatic arthritis 		Enbrel Humira Otezla Rinvoq Skyrizi Stelara Tremfya (effective 9/1/24) Xeljanz/Xeljanz XR
<i>Immunologics</i> <ul style="list-style-type: none"> Rheumatoid arthritis 		Enbrel Humira Kevzara Rinvoq Xeljanz/Xeljanz XR
<i>Multiple Sclerosis (relapsing forms)</i> <ul style="list-style-type: none"> Clinically isolated syndrome Relapsing-remitting disease Active secondary progressive disease 	Briumvi Lemtrada Ocrevus	Kesimpta



<i>PCSK9 inhibitors</i>	Leqvio	Repatha
<i>Systemic lupus erythematosus</i>	Saphnelo	IV Benlysta (Part B) SC Benlysta (Part D)

** Additional preferred products through Part D for members with open formularies include Cimzia, Cosentyx, Forteo, Olumiant, Praluent, and Tymlos.*

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. For specific medical indications subject to step therapy, please see the corresponding clinical policy bulletin on the Aetna website.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Aetna. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations, and conditions of coverage. Plan features and availability may vary by service area. The formulary and/or pharmacy network may change at any time. You will receive notice when necessary.

Aetna Better Health Premier Plan MMAI is a health plan that contracts with both Medicare and Illinois Medicaid to provide benefits of both programs to enrollees.

©2024 Aetna Inc.